Sunrest Lifescience Limited (NSE: SUNREST) is an Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹15 Cr, it ranks #4,574 by market cap among the 6,197 Indian listed companies on FinBizNet, and #59 of 63 in Pharmaceuticals. At ₹36.00 (as of 16 Nov 2026), the share price is 33.3% below its 52-week high of ₹54.00 and 21.8% above its 52-week low of ₹29.55. The share price is down 26.5% over one year and up 2.4% over three months.
| Current Price | ₹36.00 |
|---|---|
| Market Cap | ₹15 Cr |
| NSE Symbol | SUNREST |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 3.8 |
| Return on Equity | 22.43% |
| Return on Assets | 8.68% |
| 52-Week Range | ₹29.55 – ₹54.00 |
| 1-Year Price Change | -26.5% |
| 3-Month Price Change | +2.4% |
| Beta (1Y) | 0.11 |
| Headquarters | Ahmedabad, Gujarat |
| Website | sunrestlifescience.com |
Promoters held 53.50% of Sunrest Lifescience Limited's shares as of Jun 2026, against 69.91% in Jun 2025 (−16.41 percentage points).
Sunrest Lifescience Limited manufactures, sells, and markets healthcare products, medicines, and cosmetic products in India. It markets various drugs, including anti-bacterials, antibiotics, anti-amoeibics, anti- fungals, analgesic, neuropathy, anti-hypertension, anti-inflammatory, anti-ulcerants, anti-cold, anti-cough, anti-allergics, nutritionals, ayurvedic, and cosmetics in various forms, such as tablets, capsules, soft gels, syrup, dry-syrups, injections, cream-ointments, and powders. The company sells its products through a network of distributors and retailers. Sunrest Lifescience Limited was incorporated in 2017 and is based in Ahmedabad, India.
1. Trading of Goods of Pharmaceuticals-This segment offers pharmaceutical products on wholesale and retail basis. 2. NA-NA 3. NA-NA 4. NA-NA
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Sunrest Lifescience Limited | ₹15 Cr | 3.8 | 22.43% | — | -26.5% |
Listed by market capitalisation. Ratios are shown for context only.
Sunrest Lifescience Limited is trading at ₹36.00, with a market capitalisation of ₹15 Cr.
Sunrest Lifescience Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Sunrest Lifescience Limited has a P/E of 3.8 and a return on equity of 22.43%.
Sunrest Lifescience Limited is listed on the NSE under the symbol SUNREST.
Sunrest Lifescience Limited's share price is down 26.5% over one year and up 2.4% over three months. Its 52-week range is ₹29.55 to ₹54.00.
Promoters held 53.50% of Sunrest Lifescience Limited's shares as of Jun 2026, against 69.91% in Jun 2025 (−16.41 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.